Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV‐1 co‐infected patients receiving atazanavir or raltegravir ART regimens

Journal of the International AIDS Society(2014)10.7448/ias.17.4.19500Source: DataRank Database

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV‐1 co‐infected patients receiving atazanavir or raltegravir ART regimens is a research paper published in Journal of the International AIDS Society (2014). On theSindex it has a DataRank of 0.416. It has been cited 15 times.

N/A

0.416DataRank · unranked

Scored on demand from live citation data

15 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 1.84)OA: goldTopics (22)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.416

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (17)

Jay Lalezari,Jihad Slim,Joseph Gathe,Peter J Ruane,Chia Wang

Live enrichment

PubMed:25394009 PMC:PMC4224905 OpenAlex:https://openalex.org/W1985671731

NIAID NIH HHS

Grant: P30 AI050410

FWCI

1.84

Citation Percentile

0.9%

Citation Trend

2015

2016

2017

2019

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.7448/IAS.17.4.19500

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.7448/IAS.17.4.19500

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.7448%2FIAS.17.4.19500

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.7448/IAS.17.4.19500

journalhttps://doi.org/10.7448/ias.17.4.19500

Fields of Study

Hepatitis C virus researchHIV/AIDS drug development and treatmentHIV-related health complications and treatments

Keywords

MedicineRaltegravirDasabuvirAtazanavirOmbitasvirRitonavirParitaprevirRibavirinInternal medicineRegimenViral loadHepatitis CConcomitantGastroenterologySofosbuvirImmunologyHepatitis C virusHuman immunodeficiency virus (HIV)Antiretroviral therapy

Sustainable Development Goals

SDG 0: Good health and well-being

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV‐1 co‐infected patients receiving atazanavir or raltegravir ART regimens

FAIR Checklist

DataRank Breakdown

Authors (17)

Funding (1 grants)

Impact

Open Access

Topics